Department of Physiology and Pharmacology, Heart and Trauma Research Laboratory, James Cook University Townsville, QLD, Australia.
Front Physiol. 2013 Aug 28;4:228. doi: 10.3389/fphys.2013.00228. eCollection 2013.
Despite surgical proficiency and innovation driving low mortality rates in cardiac surgery, the disease severity, comorbidity rate, and operative procedural difficulty have increased. Today's cardiac surgery patient is older, has a "sicker" heart and often presents with multiple comorbidities; a scenario that was relatively rare 20 years ago. The global challenge has been to find new ways to make surgery safer for the patient and more predictable for the surgeon. A confounding factor that may influence clinical outcome is high K(+) cardioplegia. For over 40 years, potassium depolarization has been linked to transmembrane ionic imbalances, arrhythmias and conduction disturbances, vasoconstriction, coronary spasm, contractile stunning, and low output syndrome. Other than inducing rapid electrochemical arrest, high K(+) cardioplegia offers little or no inherent protection to adult or pediatric patients. This review provides a brief history of high K(+) cardioplegia, five areas of increasing concern with prolonged membrane K(+) depolarization, and the basic science and clinical data underpinning a new normokalemic, "polarizing" cardioplegia comprising adenosine and lidocaine (AL) with magnesium (Mg(2+)) (ALM™). We argue that improved cardioprotection, better outcomes, faster recoveries and lower healthcare costs are achievable and, despite the early predictions from the stent industry and cardiology, the "cath lab" may not be the place where the new wave of high-risk morbid patients are best served.
尽管心脏外科手术的精湛技术和创新使死亡率降低,但疾病的严重程度、合并症发生率和手术操作难度都有所增加。如今的心脏外科手术患者年龄更大,心脏“更脆弱”,常常伴有多种合并症;这种情况在 20 年前相对较少见。全球面临的挑战是寻找新的方法,使手术对患者更安全,对外科医生更可预测。一个可能影响临床结果的混杂因素是高钾心脏停搏液。40 多年来,钾离子去极化一直与跨膜离子失衡、心律失常和传导障碍、血管收缩、冠状动脉痉挛、收缩性顿抑和低输出综合征有关。高钾心脏停搏液除了诱导快速电化学停搏外,对成人或儿科患者几乎没有或没有内在保护作用。本综述简要回顾了高钾心脏停搏液的历史,讨论了与长时间膜钾去极化相关的五个日益令人关注的领域,以及腺苷和利多卡因(AL)加镁(Mg2+)(ALM)组成的新的正常血钾、“极化”心脏停搏液的基础科学和临床数据。我们认为,改善心肌保护、更好的结果、更快的恢复和更低的医疗成本是可以实现的,尽管支架行业和心脏病学早期有预测,但“导管室”可能不是治疗新一波高危病态患者的最佳场所。